shire map
Select a
Location

Shire Global

Europe

Americas

Asia Pacific

Pipeline

  1. Home
  2. R&D
  3. Pipeline

Our Pipeline - as of Q2 2016

Click on each of the items below for more information
and to sort columns on the right by Phase.

Phase I

Phase II

Phase III

REGISTRATION
Adynovate: Hemophilia A*

Registration

Therapeutic Area: Hematology

Type of Molecule: Protein

* Adynovate is approved in the US for 2x prophylaxis and on-demand treatment in patients with Hemophilia A, in registration in the US for surgery and pediatrics, and in registration in the EU for all three indications

Alpha-1-Antitrypsin: Acute GvHD*

Phase II

Therapeutic Area: Immunology

Type of Molecule: Protein

* Phase 3 ready program

BAX2200*

Phase III - Confirmatory

Therapeutic Area: Immunology

Type of Molecule: Protein

* Coherus Enbrel Biosimilar


BAX2923*

Phase III - Confirmatory

Therapeutic Area: Immunology

Type of Molecule: Antibodies (and derivatives)

* Momenta Humira Biosimilar


BAX826:Hemophilia A

Phase I

Therapeutic Area: Hematology

Type of Molecule: Protein

BAX930: Thrombotic Thrombocytopenic Purpura*

Phase I

Therapeutic Area: Hematology

Type of Molecule: Protein

* Phase 1/2

Calaspargase Pegol: Acute Lymphoblastic Leukemia

Phase III

Therapeutic Area: Oncology

Type of Molecule: Protein

Cinryze: AMR

Phase III

Therapeutic Area: Genetic Diseases

Type of Molecule: Protein

Cinryze: (Japan) HAE Prophylaxis

Phase III

Therapeutic Area: Genetic Diseases

Type of Molecule: Protein

Cinryze SC: HAE Prophylaxis

Phase III

Therapeutic Area: Genetic Diseases

Type of Molecule: Protein

Cuvitru: PID

Registration

Therapeutic Area: Immunology

Type of Molecule: Antibodies (and derivatives)

Firazyr: (Japan) Acute HAE

Phase III

Therapeutic Area: Genetic Diseases

Type of Molecule: Peptide

Hyqvia + Kiovig: Chronic Inflammatory Demyelinating Polyneuropathy

Phase III

Therapeutic Area: Immunology

Type of Molecule: Antibodies (and derivatives)

Imalumab: mCRC

Phase II

Therapeutic Area: Oncology

Type of Molecule: Antibodies (and derivatives)

Intuniv: (Japan) ADHD

Registration

Therapeutic Area: Neuroscience

Type of Molecule: Small Molecule

NATPAR: (EU) Hypoparathyroidism

Registration

Therapeutic Area: GI / Metabolic

Type of Molecule: Protein

Obizur: CHAWI Surgery

Phase III

Therapeutic Area: Hematology

Type of Molecule: Protein

Onivyde: (EU) Pancreatic Cancer, Post-Gemcitabine Progression

Registration

Therapeutic Area: Oncology

Type of Molecule: Small Molecule

Onivyde: (Japan) Pancreatic Cancer, Post-Gemcitabine Progression*

Phase II

Therapeutic Area: Oncology

Type of Molecule: Small Molecule

* Registration Study


Onivyde: Pancreatic Cancer, Line 1

Phase II

Therapeutic Area: Oncology

Type of Molecule: Small Molecule


Pacritinib: (EU) Myelofibrosis*

Registration

Therapeutic Area: Oncology

Type of Molecule: Small Molecule

* Program currently on full clinical hold in the US; under Regulatory review in EU

rC1-INH: (NMO)*

Phase I

Therapeutic Area: Immunology

Type of Molecule: Protein Replacement

* rC1-INH previously being developed as SHP623 for HAE prophylaxis. After Phase 1 completion will be developed for NMO.

Revestive:(Japan) Adult Short Bowel Syndrome

Phase III

Therapeutic Area: GI / Metabolic

Type of Molecule: Peptide

SHP465: ADHD*

Phase III

Therapeutic Area: Neuroscience

Type of Molecule: Small Molecule

* SHP465 received positive Phase 3 data in April (children/adolescents study), June (adults study) 2016

SHP555: Chronic Idiopathic Constipation (CIC)

Phase III

Therapeutic Area: GI / Metabolic

Type of Molecule: Small Molecule

SHP607: Neonatal Complications*

Phase II

Therapeutic Area: Ophthalmology

Type of Molecule: Protein

* SHP607 (Neonatal Complications) completed Phase 2 in June 2016

Learn more at ShireTrials.com Click Here

SHP609: Hunter IT*

Phase III

Therapeutic Area: Genetic Diseases

Type of Molecule: Protein

* Phase 2/3

Learn more at ShireTrials.com Click Here

SHP610: Sanfilippo A

Phase II

Therapeutic Area: Genetic Diseases

Type of Molecule: Protein

Learn more at ShireTrials.com Click Here

SHP611: MLD*

Phase I

Therapeutic Area: Genetic Diseases

Type of Molecule: Protein

* Phase 1/2

Learn more at ShireTrials.com Click Here

SHP620: CMV in transplant patients*

Phase II

Therapeutic Area: Oncology

Type of Molecule: Small Molecule

* Phase 3 ready program

SHP621: Eosinophilic Esophagitis (EoE)*

Phase III

Therapeutic Area: GI / Metabolic

Type of Molecule: Small Molecule

* Granted breakthrough designation by FDA

SHP625: Alagille Syndrome

Phase II

Therapeutic Area: GI / Metabolic

Type of Molecule: Small Molecule

Learn more at ShireTrials.com Click Here

SHP625: PFIC*

Phase II

Therapeutic Area: GI / Metabolic

Type of Molecule: Small Molecule

* Granted breakthrough designation for PFIC type 2

SHP626: Non-Alcoholic Steatohepatitis (NASH)

Phase II

Therapeutic Area: GI / Metabolic

Type of Molecule: Small Molecule

Learn more at ShireTrials.com Click Here

SHP631: Hunter Syndrome

Phase I

Therapeutic Area: Genetic Diseases

Type of Molecule: Protein

SHP640: Infectious Conjunctivitis*

Phase II

Therapeutic Area: Ophthalmology

Type of Molecule: Small Molecule

* Phase 3 ready program

SHP643: HAE Prophylaxis

Phase III

Therapeutic Area: Genetic Diseases

Type of Molecule: Antibodies (and derivatives)

SHP647: Crohn's Disease*

Phase II

Therapeutic Area: GI / Metabolic

Type of Molecule: Small Molecule

* Phase 3 pending regulatory feedback

SHP647: Ulcerative Colitis*

Phase II

Therapeutic Area: GI / Metabolic

Type of Molecule: Small Molecule

* Phase 3 pending regulatory feedback

SM101: Systemic Lupus Erythematosus (SLE)

Phase II

Therapeutic Area: Protein

Type of Molecule: Antibodies (and derivatives)

Vonvendi: von Willebrand Disease*

Phase 3

Therapeutic Area: Hematology

Type of Molecule: Protein

* Surgery study ongoing and pediatric/prophylaxis studies to start later this year

Vyvanse: (Japan) ADHD*

Phase III

Therapeutic Area: Neuroscience

Type of Molecule: Small Molecule

* Phase 2/3

Xiidra: Dry Eye Disease

Registration

Therapeutic Area: Ophthalmology

Type of Molecule: Small Molecule

Learn more at ShireTrials.com Click Here

JoinOurTeam

Join Our Team

We are always looking for talented individuals to join our team.

> Learn more
CommitedToResponsibility

Committed To Responsibility

We make decisions that put patients first.

> Learn more

Cookie Use Notification

The site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies as set out in our cookie notice. Please read our cookie notice for more information on the cookies we use and how to delete or block the use of cookies. LEARN MORE
CONTINUE DISAGREE